News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 This is only in lab rats, but looks very promising.  They did note that the treatments caused death because of too much swelling in a small number of the rats - that will have to be watched and treated early when they start in humans, but this has the potential to be a huge breakthrough.


Posted on: 05/13/2018

Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas 

https://www.nature.com/articles/s41591-018-0006-x

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740